Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) had its target price trimmed by Morgan Stanley from $60.00 to $45.00 in a report published on Monday, Stock Target Advisor reports. They currently have an equal weight rating on the stock.
Several other brokerages have also weighed in on BCYC. JMP Securities reaffirmed a buy rating and issued a $70.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, September 8th. Barclays started coverage on Bicycle Therapeutics in a research report on Thursday, July 28th. They issued an overweight rating and a $30.00 target price on the stock. SVB Leerink upped their target price on Bicycle Therapeutics from $48.00 to $50.00 and gave the stock an outperform rating in a research report on Monday, August 22nd. HC Wainwright lowered their price objective on Bicycle Therapeutics from $65.00 to $57.00 and set a buy rating on the stock in a report on Friday, August 5th. Finally, Canaccord Genuity Group reissued a buy rating and set a $60.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, July 6th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $55.92.
Bicycle Therapeutics Stock Down 0.4 %
NASDAQ:BCYC opened at $24.98 on Monday. The firm has a market capitalization of $741.31 million, a price-to-earnings ratio of -8.19 and a beta of 0.71. Bicycle Therapeutics has a 1-year low of $12.08 and a 1-year high of $62.08. The company has a current ratio of 9.88, a quick ratio of 9.88 and a debt-to-equity ratio of 0.10. The business’s fifty day moving average price is $23.95 and its 200 day moving average price is $25.91.
Institutional Trading of Bicycle Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Prospera Financial Services Inc bought a new stake in Bicycle Therapeutics during the 1st quarter valued at approximately $88,000. Quantbot Technologies LP bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth approximately $60,000. Claro Advisors LLC bought a new stake in shares of Bicycle Therapeutics in the 4th quarter worth approximately $221,000. Twelve Points Wealth Management LLC bought a new stake in shares of Bicycle Therapeutics in the 4th quarter worth approximately $432,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Bicycle Therapeutics in the 1st quarter worth approximately $341,000. Institutional investors own 76.45% of the company’s stock.
Bicycle Therapeutics Company Profile
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
- Get a free copy of the StockNews.com research report on Bicycle Therapeutics (BCYC)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn’t Differentiate, But it’s Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.